Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment

M Hroch, J Chladek, M Simkova, J Vaneckova, J Grim, J Martinkova

. 2008 ; 22 (1) : 19-24.

Language English Country Great Britain

Document type Clinical Trial

Grant support
NR7947 MZ0 CEP Register

Digital library NLK
Full text - Část
Source

E-resources

NLK Wiley Online Library (archiv) from 1997-01-01 to 2012-12-31

BACKGROUND: Clinical studies of low-dose oral methotrexate (MTX) in the treatment of psoriasis and rheumatoid arthritis document a large interpatient variability in the pharmacokinetics of MTX, including its polyglutamates (MTXPGs) in erythrocytes (RBC). This can be a factor contributing to the variability of therapeutic and toxic effects. AIM: This pilot trial aimed to investigate the MTXPG concentrations in RBC as well as their relation to therapeutic and adverse effects during the initial 4 months of pharmacokinetically guided therapy with a divided-dose schedule (three doses of MTX separated by 12-h intervals once a week). SUBJECTS AND METHODS: Sixteen psoriatic patients (4 men and 12 women; mean age, 53 years; range, 28-69 years) with moderate-to-severe chronic plaque psoriasis [mean Psoriasis Area and Severity Index (PASI) = 24; range, 9-42] were enrolled in the study. Concentrations of plasma MTX and that of MTXPGs in RBC were assayed using liquid chromatography methods. The area under the concentration-time curve of plasma MTX in the interval 0-8 h post-dose (AUC(0-8 h)) was measured after a test bolus dose of 10 mg, and the starting weekly dose was individualized in order to achieve the target AUC(0-8 h) of 1800 nmol.h/L. The PASI, biochemistry, and haematology tests and MTXPGs levels in RBC were evaluated at baseline and at 4-week intervals. RESULTS: The AUC(0-8 h )achieved 1360 +/- 425 nmol.h/L (mean +/- SD: range, 778-2400 nmol.h/L). The mean (range) of individualized doses was 14.5 mg/week (7.5-22.5 mg). The mean (SD) steady-state concentration of total MTXPGs observed between days 85 to 110 reached 113 (34.6) nmol/L (range, 66.1-174 nmol/L). The PASI decreased from 24.0 +/- 8.0 (mean +/- SD) at baseline to 8.0 +/- 6.1 at day 110 (P < 0.001). Thirteen patients (87%) achieved a greater than 50% improvement in baseline PASI, and seven (47%) experienced a greater than 75% improvement. There was no relationship between the percent improvement from baseline PASI and the steady-state concentration of MTXPGs in RBC. All patients tolerated MTX well. Throughout the study period, there was a continuous increasing trend in the geometric mean values of the mean corpuscular volume from 92.6 to 96.4 fL (P < 0.001) and of plasma homocysteine from 9.5 to 12.3 micromol/L (P < 0.005). The geometric mean serum alanine aminotransferase (ALT) activity slightly increased from 0.49 to 0.80 microkat/L (P < 0.05). However, only two patients had the ALT activity transiently elevated above twice the upper limit of normal. CONCLUSION: Results of this pilot trial show that the steady-state levels of MTXPGs in RBC vary less than threefold between patients and did not correlate with the change in PASI observed after 4 months of therapy with an individualised weekly dose of MTX. Whether pharmacokinetically guided dosing can improve the results of psoriasis therapy with MTX should be prospectively tested in large controlled studies.

000      
00000naa 2200000 a 4500
001      
bmc10026317
003      
CZ-PrNML
005      
20130917102438.0
008      
101018s2008 xxk e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hroch, Miloš, $d 1976- $7 xx0076212
245    12
$a A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment / $c M Hroch, J Chladek, M Simkova, J Vaneckova, J Grim, J Martinkova
314    __
$a Department of Pharmacology, Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic.
520    9_
$a BACKGROUND: Clinical studies of low-dose oral methotrexate (MTX) in the treatment of psoriasis and rheumatoid arthritis document a large interpatient variability in the pharmacokinetics of MTX, including its polyglutamates (MTXPGs) in erythrocytes (RBC). This can be a factor contributing to the variability of therapeutic and toxic effects. AIM: This pilot trial aimed to investigate the MTXPG concentrations in RBC as well as their relation to therapeutic and adverse effects during the initial 4 months of pharmacokinetically guided therapy with a divided-dose schedule (three doses of MTX separated by 12-h intervals once a week). SUBJECTS AND METHODS: Sixteen psoriatic patients (4 men and 12 women; mean age, 53 years; range, 28-69 years) with moderate-to-severe chronic plaque psoriasis [mean Psoriasis Area and Severity Index (PASI) = 24; range, 9-42] were enrolled in the study. Concentrations of plasma MTX and that of MTXPGs in RBC were assayed using liquid chromatography methods. The area under the concentration-time curve of plasma MTX in the interval 0-8 h post-dose (AUC(0-8 h)) was measured after a test bolus dose of 10 mg, and the starting weekly dose was individualized in order to achieve the target AUC(0-8 h) of 1800 nmol.h/L. The PASI, biochemistry, and haematology tests and MTXPGs levels in RBC were evaluated at baseline and at 4-week intervals. RESULTS: The AUC(0-8 h )achieved 1360 +/- 425 nmol.h/L (mean +/- SD: range, 778-2400 nmol.h/L). The mean (range) of individualized doses was 14.5 mg/week (7.5-22.5 mg). The mean (SD) steady-state concentration of total MTXPGs observed between days 85 to 110 reached 113 (34.6) nmol/L (range, 66.1-174 nmol/L). The PASI decreased from 24.0 +/- 8.0 (mean +/- SD) at baseline to 8.0 +/- 6.1 at day 110 (P < 0.001). Thirteen patients (87%) achieved a greater than 50% improvement in baseline PASI, and seven (47%) experienced a greater than 75% improvement. There was no relationship between the percent improvement from baseline PASI and the steady-state concentration of MTXPGs in RBC. All patients tolerated MTX well. Throughout the study period, there was a continuous increasing trend in the geometric mean values of the mean corpuscular volume from 92.6 to 96.4 fL (P < 0.001) and of plasma homocysteine from 9.5 to 12.3 micromol/L (P < 0.005). The geometric mean serum alanine aminotransferase (ALT) activity slightly increased from 0.49 to 0.80 microkat/L (P < 0.05). However, only two patients had the ALT activity transiently elevated above twice the upper limit of normal. CONCLUSION: Results of this pilot trial show that the steady-state levels of MTXPGs in RBC vary less than threefold between patients and did not correlate with the change in PASI observed after 4 months of therapy with an individualised weekly dose of MTX. Whether pharmacokinetically guided dosing can improve the results of psoriasis therapy with MTX should be prospectively tested in large controlled studies.
650    _2
$a aplikace orální $7 D000284
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a dermatologické látky $x aplikace a dávkování $x farmakokinetika $x krev $7 D003879
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a nežádoucí účinky léčiv $7 D064420
650    _2
$a erytrocyty $x metabolismus $7 D004912
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methotrexát $x aplikace a dávkování $x farmakokinetika $x krev $7 D008727
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pilotní projekty $7 D010865
650    _2
$a psoriáza $x farmakoterapie $x krev $7 D011565
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a výsledek terapie $7 D016896
650    _2
$a financování organizované $7 D005381
655    _2
$a klinické zkoušky $7 D016430
700    1_
$a Chládek, Jaroslav, $d 1962- $7 xx0057856
700    1_
$a Šimková, Marie $7 xx0153126
700    1_
$a Vaněčková, Jaroslava, $d 1945- $7 jn20020220009
700    1_
$a Grim, Jiří $7 xx0143078
700    1_
$a Martínková, Jiřina, $d 1940- $7 nlk19990073537
773    0_
$w MED00002983 $t Journal of the European Academy of Dermatology and Venereology $g Roč. 22, č. 1 (2008), s. 19-24 $x 0926-9959
910    __
$a ABA008 $b x $y 7
990    __
$a 20101116104621 $b ABA008
991    __
$a 20130917102943 $b ABA008
999    __
$a ok $b bmc $g 801422 $s 666168
BAS    __
$a 3
BMC    __
$a 2008 $b 22 $c 1 $d 19-24 $m Journal of the European Academy of Dermatology and Venereology $n J Eur Acad Dermatol Venerol $x MED00002983
GRA    __
$a NR7947 $p MZ0
LZP    __
$a 2010-B/jtme

Find record